← Feed

u/Weekly-Barracuda-494

2 theses · first seen Sep 4, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d1100%-1.2%-1.2%
3d1100%-7.7%-7.7%
1w1100%-19.8%-19.8%
1m1100%-17.4%-17.4%
3m000———
6m000———
1y000———

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$FBIOr/pennystocksGeneral Discussionbullish
u/Weekly-Barracuda-494 · 46d ago1 prior · awaiting results

FBIO Positioned for Growth?

Fortress Biotech is a diversified biotech holding company with a market cap of $110M while generating ~$86M in projected sales from Journey Medical alone. The company has multiple near-term revenue catalysts (Journey Medical profitability, dotinurad royalties, Unloxcyt sales, and Zycubo milestone payments) and a strong balance sheet ($200M cash, 20-25% debt-to-equity), positioning it as a potential multi-bagger despite accumulated preferred dividend obligations.

At post $3.39Now $2.52-25.7% since postedas of Sep 11, 4:30 PM ET
1d-1.2%
3d-7.7%
1w-19.8%
1m-17.4%
3m—
6m—
1y—
original post →
$SPROr/pennystocksGeneral Discussionbullish
u/Weekly-Barracuda-494 · 60d ago1 prior · awaiting results

Spero Therapeutics Changing focus

Spero Therapeutics monetized GSK royalties to fund an asset acquisition from Innovent Biologics, positioning the company to run Phase 2/3 trials on a new antibody program with sufficient capital on hand and up to $326M in milestone payments from GSK, potentially avoiding dilution.

At post $1.70Now $1.13-33.5% since postedas of Sep 11, 4:30 PM ET
original post →

End of results.